Wednesday, October 28, 2026HotTea verified storyVerified 12:17 AM PDT
← Back to the Wednesday, October 28, 2026 edition

BigHat and Anthropic improve two antibody leads in lab tests

BigHat and Anthropic reported an antibody-engineering collaboration on October 27. One Anthropic researcher worked with Claude while BigHat's lab made and tested designs. The collaborators describe work on two antibody leads over about 10 weeks. They report better binding, stability, and resistance to clumping in selected variants.

Verified 12:17 AM PDT · 2 original sources

Both accounts come from interested collaborators, without independent replication reported here. These are laboratory properties of two antibody leads, not evidence that a new medicine works in patients. BigHat also says the team changed how instrument readings were interpreted after unreliable measurements appeared.

Examine the technical report, assay changes, and results from other laboratories. Better lab measurements still need to translate into a drug candidate that can pass later testing.

Audit the story

Original sources

Company claims remain company claims. Follow the reporting and judge the evidence directly.

  1. AnthropicEarly progress on accelerating drug development with Claude ↗
  2. BigHat BiosciencesAgents at the bench: Anthropic and BigHat collaborate on rapid agentic-driven therapeutic antibody optimization ↗

Continue the edition

Read the full edition.

Read the full editionListen to the daily audio →